Net Asset Value(s)

The table reports VanEck fund NAVs dated 2026-11-02. VanEck AEX UCITS ETF had net assets of 447,517,691.04 across 3,938,777 shares in issue and NAV per share of 113.6184; Multi-Asset Balanced reported 42,237,024.83 in net assets and NAV per share of 77.7846, while Multi-Asset Growth reported 34,633,349.61 and 93.6036, respectively. The final fund row is truncated.

Analysis

This is a fund-level NAV snapshot, not evidence of a change in underlying asset value, investor demand, or strategy. Without prior-period NAVs, market prices, holdings, or flows, the figures do not establish performance or support a directional trade. The AEX fund’s NAV is principally a wrapper around Dutch large-cap equity exposure; any investment implication should come from the underlying constituents and their earnings or macro outlook, not the NAV figure alone. For the multi-asset funds, the asset-allocation labels are insufficient to infer equity, duration, or currency sensitivities. The final fund row is incomplete, which limits even basic comparison across products. Near term, the only actionable angle is an operational check for a material market-price/NAV premium or discount and adequate liquidity; no such gap is provided. Over the next 1–3 months, holdings, flows, and comparable NAV history would be needed to identify relative performance or allocation shifts. No clear catalyst or contrarian signal is present in this data alone.

Key Decisions for Investors

• No directional trade: the snapshot lacks prior NAVs, market prices, holdings, and flow data needed to distinguish performance from fund-size changes.
• Verify the incomplete final row and obtain full fund names, holdings, and historical NAVs before comparing products or inferring allocation exposure.
• Monitor quoted market price versus NAV and trading liquidity; investigate only if a persistent, material premium or discount appears.
• A trade thesis would be falsified—or remain unsupported—if subsequent NAV and price data show no meaningful relative divergence or if the underlying holdings do not confirm the expected exposure.